Grace Therapeutics, Inc.

The company focuses on developing and selling products for rare and orphan diseases. It aims to improve patient outcomes by using novel drug delivery technologies and applying new proprietary formulations to existing approved and marketed pharmaceutical compounds. This approach seeks to achieve enhanced effectiveness, faster action, fewer side effects, easier drug delivery, and better patient adherence. The active ingredients in the company's drug candidates may already be approved for a specific use or could be used for new conditions. The therapeutic pipeline includes three clinical-stage drug candidates, supported by an intellectual property portfolio of more than 40 granted and pending patents globally. These candidates aim to improve treatment for rare and orphan diseases by enhancing existing pharmaceutical compounds or providing therapies for diseases without current approved treatments. The company utilizes the Section 505(b)(2) regulatory pathway under the Federal Food, Drug and Cosmetic Act ("FDCA") for its reformulated drugs. This pathway may shorten the time to regulatory approval by potentially reducing the need for some pre-clinical studies and clinical trials, given the established efficacy and safety profiles of the marketed compounds. The company believes rare disorders are an attractive area for drug development, offering an opportunity to address unmet medical needs using approved drugs with known safety profiles. Pursuing therapies for rare disorders also offers the potential to receive orphan drug designation ("ODD") from the FDA.